Background

The subscription price for the warrants was previously determined to a subscription price equivalent to 70 percent of the volume-weighted average price during the pricing period from and including 1 February 2024 up to and including 15 February 2024, however, be no less than the share's current quota value rounded up to two decimal places, which amounted to 0.02 SEK per share and a maximum of 0.15 SEK.

Due to the recently completed reverse share split, a recalculation of both the range, subscription price, and the number of series TO3 warrants required for subscription of new shares was made. After the reverse share split, the total number of shares in the Company decreased from 724,595,100 shares to 7,245,951 shares. The shares then had a quota value of SEK 1.725 per share. The range of the subscription price was no less than the share's current quota value rounded up to two decimal places, which corresponds to SEK 1.73 per share and a maximum of SEK 15 per share. 70 percent of the volume-weighted average price during the measurement period was below 1.73 SEK, and thus, the subscription price was set at 1.73 SEK. As a result of the reverse share split, one hundred (100) series TO3 warrants are required to subscribe for one (1) new share.

Final outcome and subscription price of TO3

To ensure that the Company could carry out the Rights Issue, the EGM resolved on a reduction of the share capital in order to reduce the quota value to SEK 0.40. However, the reduction of the share capital has not yet been registered with the Swedish Companies Registration Office. In consideration of this, the board of directors has resolved on an additional recalculation of the subscription price for the series TO3 warrants, entailing that the subscription price for the series TO3 warrants is at least the resolved but not registered quota value of the share, which is 0.40 SEK. 70 percent of the volume-weighted average price during the pricing period for TO3 amounted to SEK 0.97 per share, and thus, the subscription price is determined to be SEK 0.97 per share.

In total, 439,100 warrants were exercised, corresponding to approximately 0.15 percent of all series TO3 warrants, for the subscription of a total of 4,391 shares. Through the exercised warrants, NeoDynamics will thereby receive approximately 4,300 SEK before transaction costs.

The difference between the amount paid and the final subscription price will be repaid.

Increase in the number of shares and share capital

By exercising the warrants, the number of shares in NeoDynamics increases with 4,391 shares, from 7,245,951 to 7,250,342 shares. The share capital increases preliminarily with 1,756.40 SEK, from 12,499,265.475 SEK to 12,501,021.875 SEK. For existing shareholders who have not exercised any warrants, the dilution is approximately 0.06 percent based on the number of shares in NeoDynamics after the exercise of the warrants.

Delivery of new shares

Subscribers of new shares through the exercise of warrants have received interim shares (IA) pending the registration of the new shares with the Swedish Companies Registration Office. The shares will be registered in connection with the registration of the shares in the Rights Issue. The conversion of interim shares to ordinary shares is expected to take place around week 14, and the new ordinary shares will then be listed for trading on the Nasdaq First North Growth Market.

Advisers

Redeye AB is a financial advisor in connection with the Rights Issue. Advokatfirman Lindahl KB acts as legal advisor to NeoDynamics in connection with the Rights Issue. Nordic Issuing AB acts as the issuing agent in connection with the Rights Issue.

For further information, please contact:

Matilda Salen, CEO NeoDynamics AB, phone +4676 843 65 74 or e-mail matilda.salen@neodynamics.com

Aaron Wong, CFO NeoDynamics AB, phone +4673 597 20 11 or e-mail aaron.wong@neodynamics.com

About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. NeoNavia® is CE approved, and in September 2022, received a 510k approval from the FDA. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia®

NeoNavia® is the trade name for the complete biopsy system intended for use in ultrasound-guided sampling. NeoNavia® consists of a base unit, a hand unit, and three types of biopsy needles. The pulse technology drives the respective needle type, which facilitates needle insertion and placement in the suspected tumor. The system is designed to offer physicians and patients precise and robust tissue sampling for accurate diagnosis and individualized treatment.

About the pulse technology

The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, regardless of tissue type. The pneumatic drive unit that generates pulses is located in a hand-held instrument. With power from the base unit, the hand-held driver accelerates the biopsy needle with great control, even over short distances, enabling a distinct step-by-step insertion without affecting the surrounding tissue. This enables good access and flexibility in sampling, even in tiny and tricky localized tumors.

For more information, please visit Neodynamics.com.

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in NeoDynamics. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in NeoDynamics has only been made through the prospectus published by NeoDynamics on 31 July 2023, and through the supplement prospectuses published by NeoDynamics on 11 August 2023. The prospectuses have been approved and registered by the Swedish Financial Supervisory Authority and have been published on the Company’s website, www.neodynamics.com.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.